Jiaodi Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiaodi Cai has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Wenqin Zhang
Department of Pathology, The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University), Changsha, China
2 shared publications - Feng Jiang
Department of Pathology, The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University), Hunan, China
1 shared publication - Huiting Yang
The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University)
1 shared publication - Li Xiao
Department of Pathology, The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University), Hunan, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Myxoid malignant solitary fibrous tumor in the retroperitoneum: A case report and literature review
Solitary fibrous tumor (SFT) is a spectrum of mesenchymal tumors characterized by a branching (staghorn-like) vascular pattern and the specific NAB2 :: STAT6 gene fusion. Myxoid SFT is a rare histological variant defined by myxoid stroma constituting over 50% of the tumor volume. Although most myxoid SFTs exhibit benign or indolent behavior, recent reports have demonstrated that this variant can also exhibit aggressive biological behavior. To our knowledge, malignant myxoid SFT arising in the retroperitoneum with integrative clinicopathological and molecular characterization has been rarely documented. We report a case of malignant myxoid SFT arising in the retroperitoneum and discuss its clinicopathological features with a literature review. A woman in her mid-50s presented with lower abdominal pain for over one month. Imaging revealed a pelvic mass that was initially clinically diagnosed as a uterine leiomyoma. Intraoperative exploration identified the mass in the retroperitoneum, and complete resection was performed. Gross examination showed a tumor measuring 11 cm in greatest dimension with a gray-white to gray-red, soft cut surface, predominantly gelatinous in appearance. Histopathological examination revealed a spindle cell tumor with prominent myxoid stroma (approximately 60% of the tumor volume), a mitotic count of approximately 10/10 high-power fields (HPF; equivalent to 5/mm 2 ), and coagulative tumor necrosis (approximately 15%). Immunohistochemistry demonstrated diffuse strong positivity for CD34 and STAT6, weak positivity for Bcl-2, and focal weak positivity for CDK4 and MDM2. DNA-based next-generation sequencing (NGS) detected an NAB2 :: STAT6 fusion gene and no MDM2 amplification, confirming the diagnosis of myxoid malignant SFT. According to the modified Demicco risk stratification model (age ≥55 years, tumor size 11 cm, mitotic count ≥4/10 HPF, necrosis ≥10%), the case scored 6 points, placing it in the high-risk category. The patient received adjuvant radiotherapy (45 Gy in 25 fractions to the PCTV) and remained disease-free without evidence of recurrence or metastasis throughout the 17-month follow-up period. Malignant myxoid SFT arising in the retroperitoneum is extremely rare and poses significant diagnostic challenges. Accurate diagnosis can be supported by histopathological and immunohistochemical examinations (including CD34, STAT6, and BCL2), and molecular detection of the NAB2 :: STAT6 fusion gene can serve as a valuable adjunct, especially in cases where morphological and immunohistochemical findings are atypical or when differential diagnosis is challenging. Complete surgical resection is the cornerstone of treatment. Adjuvant therapy and close long-term surveillance should be considered for patients with high-risk features. To the best of our knowledge, this case supplements the clinicopathological data of this rare entity occurring in the retroperitoneum with overt malignant biological behavior, and further case reports and studies are essential to refine the diagnostic criteria and optimize treatment strategies for this tumor.
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessMyxoid malignant solitary fibrous tumor in the retroperitoneum: A case report and literature review
Solitary fibrous tumor (SFT) is a spectrum of mesenchymal tumors characterized by a branching (staghorn-like) vascular pattern and the specific NAB2 :: STAT6 gene fusion. Myxoid SFT is a rare histological variant defined by myxoid stroma constituting over 50% of the tumor volume. Although most myxoid SFTs exhibit benign or indolent behavior, recent reports have demonstrated that this variant can also exhibit aggressive biological behavior. To our knowledge, malignant myxoid SFT arising in the retroperitoneum with integrative clinicopathological and molecular characterization has been rarely documented. We report a case of malignant myxoid SFT arising in the retroperitoneum and discuss its clinicopathological features with a literature review. A woman in her mid-50s presented with lower abdominal pain for over one month. Imaging revealed a pelvic mass that was initially clinically diagnosed as a uterine leiomyoma. Intraoperative exploration identified the mass in the retroperitoneum, and complete resection was performed. Gross examination showed a tumor measuring 11 cm in greatest dimension with a gray-white to gray-red, soft cut surface, predominantly gelatinous in appearance. Histopathological examination revealed a spindle cell tumor with prominent myxoid stroma (approximately 60% of the tumor volume), a mitotic count of approximately 10/10 high-power fields (HPF; equivalent to 5/mm 2 ), and coagulative tumor necrosis (approximately 15%). Immunohistochemistry demonstrated diffuse strong positivity for CD34 and STAT6, weak positivity for Bcl-2, and focal weak positivity for CDK4 and MDM2. DNA-based next-generation sequencing (NGS) detected an NAB2 :: STAT6 fusion gene and no MDM2 amplification, confirming the diagnosis of myxoid malignant SFT. According to the modified Demicco risk stratification model (age ≥55 years, tumor size 11 cm, mitotic count ≥4/10 HPF, necrosis ≥10%), the case scored 6 points, placing it in the high-risk category. The patient received adjuvant radiotherapy (45 Gy in 25 fractions to the PCTV) and remained disease-free without evidence of recurrence or metastasis throughout the 17-month follow-up period. Malignant myxoid SFT arising in the retroperitoneum is extremely rare and poses significant diagnostic challenges. Accurate diagnosis can be supported by histopathological and immunohistochemical examinations (including CD34, STAT6, and BCL2), and molecular detection of the NAB2 :: STAT6 fusion gene can serve as a valuable adjunct, especially in cases where morphological and immunohistochemical findings are atypical or when differential diagnosis is challenging. Complete surgical resection is the cornerstone of treatment. Adjuvant therapy and close long-term surveillance should be considered for patients with high-risk features. To the best of our knowledge, this case supplements the clinicopathological data of this rare entity occurring in the retroperitoneum with overt malignant biological behavior, and further case reports and studies are essential to refine the diagnostic criteria and optimize treatment strategies for this tumor.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Angiomatoid fibrous histiocytoma with CDK4 and MDM2 expression misdiagnosed as dedifferentiated liposarcoma: The first case report and literature review
Angiomatoid fibrous histiocytoma is a rare intermediate soft tissue tumor with uncertain differentiation and prone to misdiagnosis because of atypical morphology and aberrant biomarker expression. Herein, we report a unique case of occipital scalp angiomatoid fibrous histiocytoma in a 33-year-old female, which presented with rapid tumor growth, marked nuclear pleomorphism, elevated mitotic activity, and atypical positive expression of CDK4 and MDM2 immunohistochemically, leading to an initial misdiagnosis of dedifferentiated liposarcoma. Preoperative routine blood tests, biochemical examinations, and inflammatory biomarker detection, including C-reactive protein, erythrocyte sedimentation rate, and interleukin-6, were performed, and all hematological indicators were within normal reference ranges without systemic inflammatory or hematological abnormalities. The patient underwent complete marginal resection of the tumor, and no adjuvant radiotherapy or chemotherapy was administered postoperatively because of the absence of high-risk malignant features, residual lesions, and distant metastasis. Molecular testing confirmed EWSR1 gene rearrangement without CDK4 or MDM2 gene amplification, which confirmed the final diagnosis of angiomatoid fibrous histiocytoma. The patient achieved a favorable prognosis with no recurrence or metastasis during 20 months of postoperative follow-up. Distinct from previously reported conventional angiomatoid fibrous histiocytoma cases with low proliferative activity and negative liposarcoma-related markers, the present case is characterized by atypical dual positive expression of CDK4/MDM2 and a markedly elevated Ki-67 proliferation index, which fills the clinical data gap of atypical angiomatoid fibrous histiocytoma with liposarcoma-mimicking immunophenotype. This study further clarifies the differential diagnostic criteria between angiomatoid fibrous histiocytoma and dedifferentiated liposarcoma, verifies that isolated CDK4/MDM2 immunohistochemical positivity cannot independently support the diagnosis of liposarcoma, and highlights the irreplaceable value of molecular testing in the definitive diagnosis of atypical angiomatoid fibrous histiocytoma, providing a reliable reference for pathologists to avoid diagnostic errors in similar rare soft tissue tumors.
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessAngiomatoid fibrous histiocytoma with CDK4 and MDM2 expression misdiagnosed as dedifferentiated liposarcoma: The first case report and literature review
Angiomatoid fibrous histiocytoma is a rare intermediate soft tissue tumor with uncertain differentiation and prone to misdiagnosis because of atypical morphology and aberrant biomarker expression. Herein, we report a unique case of occipital scalp angiomatoid fibrous histiocytoma in a 33-year-old female, which presented with rapid tumor growth, marked nuclear pleomorphism, elevated mitotic activity, and atypical positive expression of CDK4 and MDM2 immunohistochemically, leading to an initial misdiagnosis of dedifferentiated liposarcoma. Preoperative routine blood tests, biochemical examinations, and inflammatory biomarker detection, including C-reactive protein, erythrocyte sedimentation rate, and interleukin-6, were performed, and all hematological indicators were within normal reference ranges without systemic inflammatory or hematological abnormalities. The patient underwent complete marginal resection of the tumor, and no adjuvant radiotherapy or chemotherapy was administered postoperatively because of the absence of high-risk malignant features, residual lesions, and distant metastasis. Molecular testing confirmed EWSR1 gene rearrangement without CDK4 or MDM2 gene amplification, which confirmed the final diagnosis of angiomatoid fibrous histiocytoma. The patient achieved a favorable prognosis with no recurrence or metastasis during 20 months of postoperative follow-up. Distinct from previously reported conventional angiomatoid fibrous histiocytoma cases with low proliferative activity and negative liposarcoma-related markers, the present case is characterized by atypical dual positive expression of CDK4/MDM2 and a markedly elevated Ki-67 proliferation index, which fills the clinical data gap of atypical angiomatoid fibrous histiocytoma with liposarcoma-mimicking immunophenotype. This study further clarifies the differential diagnostic criteria between angiomatoid fibrous histiocytoma and dedifferentiated liposarcoma, verifies that isolated CDK4/MDM2 immunohistochemical positivity cannot independently support the diagnosis of liposarcoma, and highlights the irreplaceable value of molecular testing in the definitive diagnosis of atypical angiomatoid fibrous histiocytoma, providing a reliable reference for pathologists to avoid diagnostic errors in similar rare soft tissue tumors.